SIGNIFICANT ONGOING CLINICAL TRIALS

• Prioritizing Targeted Agents for Pediatric Clinical Evaluation

Early Phase Trial

• Targeted Therapy Combinations in Glioma, Melanoma, and Renal Cell Cancer

Definitive, Late Phase Trials

• A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
• Phase III Study of R-CHOP versus R-Dose-Adjusted-Epoch with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
• Trial Assessing Individualized Options for Treatment (TAILORx) in the Adjuvant Setting for Women with Breast Cancer
• Randomized Trials Evaluate the Addition of Bevacizumab or Cetuximab in Combination with Chemotherapy in Patients with Resected Colon Cancer
• Incorporating Novel Agents into the Treatment of Pediatric Acute Lymphoblastic Leukemia
• Phase III Treatment Trials in Early Stage Non-Small Cell Lung Cancer Will Assess the Clinical Benefit of Bevacizumab as Part of Adjuvant Therapy and Surgical Resection Techniques
• Phase III Trial in Advanced Non-Small Cell Lung Cancer Will Assess FDG-PET/CT as Predictive Marker of Response and Patient Outcome
• Phase III Trial Evaluating Radiotherapy to the Pelvic Lymph Nodes with Short-Term Androgen Deprivation in Prostate Cancer Patients with a Rising Prostate-Specific Antigen after Radical Prostatectomy
• International Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study—The ALTTO Study